Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 Injection in Type 2 Diabetes Mellitus (Phase II)
CTR20232258Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2023; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20232258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232258.